// App-Quantinova.ai

8088 : A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).

Researchers

Presenter

  • Joel W. Neal

Principal Investigators

  • Heather A. Wakelee

  • Josephine Louella Feliciano

  • Millie Snigdha Das

  • Rebecca Suk Heist

  • Inga Tolin Lennes

  • Alona Muzikansky

  • Martin J. Edelman

  • Scott N. Gettinger

Medical Centers

  • University of New Mexico Cancer Center, Albuquerque, NM

  • Massachusetts General Hospital Cancer Center, Boston, MAStanford Cancer Institute, Stanford, CAWashington University School of Medicine in St. Louis, St. Louis, MO

  • Palo Alto Veterans Affairs Medical Center/Stanford University School of Medicine, Stanford, CA

  • Yale University, New Haven, CT

  • University of Maryland Greenebaum Cancer Center, Baltimore, MD

  • Department of Medical Oncology, Yale University School of Medicine, New Haven, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Erlotinib hydrochloride

Outcome

  • Positive

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT00977470

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved